Optical Study of Diamine Coupling on Carboxyl-Functionalized Mesoporous Silicon

Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects

DNA methyltransferase inhibitors have improved the prognosis of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). However, because these agents are easily degraded by cytidine deaminase (CDA), they must be administered intravenously or subcutaneously. Recently, two orally bioavailable DNA methyltransferase inhibitors, CC-486 and ASTX727, were approved. In previous work, we developed 5-O-trialkylsilylated decitabines that resist degradation by CDA. However, the effects of silylation of a deoxynucleotide analog and enzymatic cleavage of silylation have not been fully elucidated. Enteric administration of OR21 in a cynomolgus monkey model led to high plasma concentrations and hypomethylation, and in a mouse model, oral administration of enteric-coated OR21 led to high plasma concentrations. The drug became biologically active after release of decitabine (DAC) from OR21 following removal of the 5'-O-trisilylate substituent. Toxicities were tolerable and lower than those of DAC. Transcriptome and methylome analysis of MDS and AML cell lines revealed that OR21 increased expression of genes associated with tumor suppression, cell differentiation, and immune system processes by altering regional promoter methylation, indicating that these pathways play pivotal roles in the action of hypomethylating agents. OR21 induced cell differentiation via upregulation of the late cell differentiation drivers CEBPE and GATA-1 Thus, silylation of a deoxynucleotide analog can confer oral bioavailability without new toxicities. Both in vivo and in vitro, OR21 exerted antileukemia effects, and had a better safety profile than DAC. Together, our findings indicate that OR21 is a promising candidate drug for phase I study as an alternative to azacitidine or decitabine.

Porous Si Microparticles Infiltrated with Magnetic Nanospheres

Porous silicon (pSi) microparticles obtained by porosification of crystalline silicon wafers have unique optical properties that, together with biodegradability, biocompatibility and absence of immunogenicity, are fundamental characteristics to candidate them as tracers in optical imaging techniques and as drug carriers. In this work, we focus on the possibility to track down the pSi microparticles also by MRI (magnetic resonance imaging), thus realizing a comprehensive tool for theranostic applications, i.e., the combination of therapy and diagnostics. We have developed and tested an easy, quick and low-cost protocol to infiltrate the COOH-functionalized pSi microparticles pores (tens of nanometers about) with magnetic nanospheres (SPIONs-Super Paramagnetic Iron Oxide Nanoparticles, about 5-7 nm) and allow an electrostatic interaction. The structural properties and the elemental composition were investigated by electron microscopy techniques coupled to elemental analysis to demonstrate the effective attachment of the SPIONs along the pores' surface of the pSi microparticles. The magnetic properties were investigated under an external magnetic field to determine the relaxivity properties of the material and resulting in an alteration of the relaxivity of water due to the SPIONs presence, clearly demonstrating the effectiveness of the easy functionalization protocol proposed.

Facile synthesis of amino-functional large-size mesoporous silica sphere and its application for Pb2+ removal

Amino-functional large-size mesoporous silica spheres (LMS-AP) were successfully synthesized through a one-step method with (3-aminopropyl) triethoxysilane (APTES) addition during the pseudomorphic transformation process. LMS-AP were characterized using thermogravimetry-differential thermal analysis, Nitrogen adsorption-desorption measurement, infrared spectroscopy, and X-ray photoelectron spectroscopy. The study found that -NH₂ was grafted into LMS, and the LMS-AP had a better thermal stability than other samples. The Pb²⁺ removal properties of LMS-AP were investigated using the static and dynamic experiments in simulated and real wastewater solutions. The kinetic and equilibrium experiments indicated that the adsorption process of LMS-AP fitted the Langmuir adsorption model and the pseudo-second-order kinetics model (R² > 0.98), respectively. The maximum Q_e (mg/g) was about 100 mg/g in the static adsorption condition. The adsorption mechanism of removal of Pb²⁺ was also investigated. In fix bed column experiments, LMS-AP exhibited excellent Pb²⁺ adsorption ability for simulated wastewater, with the maximum q_e (mg/g) of 48.7 mg/g for particle size under 1-3 mm. Meanwhile in actual industrial wastewater treatment process, LMS-AP had a better Pb²⁺, Zn²⁺ and Cr (VI) removal efficiency of 80% and As (V) of 30-40% removal efficiency at initial pH 4, suggesting selective adsorption property for different heavy metal ions.

Hybrid luminescent porous silicon for efficient drug loading and release

In recent decades, biocompatible and light emitting porous silicon (pSi) showed the possibility for use in biomedical applications.